Lymphoma, Primary Cutaneous Anaplastic Large Cell - 4 Studies Found

Active, not recruiting : A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
:
  • Primary Cutaneous Anaplastic Large Cell Lymphoma
  • Mycosis Fungoi
    : 2012-03-27
    :
    • Drug: Brentuximab Vedotin Bren
Completed : Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
:
  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrom
    : 2010-05-28
    :
    • Drug: Pralatrexate Injection

Active, not recruiting : SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
:
  • CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma
  • Lymphoma, Pr
    : 2011-05-10
    : Drug: SGN-35 1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day
Recruiting : Multicentre Phase I Trial of Engineered T Cells for Patients With Relapsed or Refractory Primary Cutaneous CD30+ Large T Cell Lymphoma or Transformed CD30+ Mycosis Fungoides
:
  • CD30 Positive Cutaneous T Cell Lymphoma
  • CD30 Positive Transformed Mycosis Fungoides
    • : 2012-07-11
    : Genetic: Genetically modified T cells # 1138